<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36965406</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-7753</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Stem cell research</Title><ISOAbbreviation>Stem Cell Res</ISOAbbreviation></Journal><ArticleTitle>Generation of two induced pluripotent stem cell lines with heterozygous and homozygous amyotrophic lateral sclerosis-causing mutation R521G (c.1561C&#xa0;&gt;&#xa0;G) in FUS gene.</ArticleTitle><Pagination><StartPage>103078</StartPage><MedlinePgn>103078</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.scr.2023.103078</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1873-5061(23)00064-8</ELocationID><Abstract><AbstractText>Mutations in the RNA-binding protein FUS (fused in sarcoma) are linked to amyotrophic lateral sclerosis (ALS), but the pathogenesis is not fully understood. For modeling ALS, here we generated two induced pluripotent stem cell (iPSC) lines carrying the heterozygous and homozygous R521G (c.1561C&#xa0;&gt;&#xa0;G) mutation in the FUS gene via genetic modification of a healthy hiPSC line (WTC11, UCSFi001-A). Both lines show normal stem cell morphology and karyotype, express pluripotent markers, and can differentiate into three germ layers, providing a valuable resource in determining the pathological mechanisms underlying the FUS mutation of R521G in ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akter</LastName><ForeName>Masuma</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences, Center at Shreveport, Shreveport, LA 71130-3932, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Haochen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences, Center at Shreveport, Shreveport, LA 71130-3932, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abir Hosain</LastName><ForeName>Md</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences, Center at Shreveport, Shreveport, LA 71130-3932, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Baojin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences, Center at Shreveport, Shreveport, LA 71130-3932, USA. Electronic address: Baojin.Ding@lsuhs.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS112910</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stem Cell Res</MedlineTA><NlmUniqueID>101316957</NlmUniqueID><ISSNLinking>1873-5061</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059785" MajorTopicYN="N">Karyotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>25</Day><Hour>19</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36965406</ArticleId><ArticleId IdType="mid">NIHMS1906527</ArticleId><ArticleId IdType="pmc">PMC10353567</ArticleId><ArticleId IdType="doi">10.1016/j.scr.2023.103078</ArticleId><ArticleId IdType="pii">S1873-5061(23)00064-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akter M, Cui H, Chen YH, Ding B, 2021. Generation of two induced pluripotent stem cell lines with heterozygous and homozygous GAG deletion in TOR1A gene from a healthy hiPSC line. Stem Cell Res. 56, 102536 10.1016/j.scr.2021.102536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2021.102536</ArticleId><ArticleId IdType="pmc">PMC8561712</ArticleId><ArticleId IdType="pubmed">34536661</ArticleId></ArticleIdList></Reference><Reference><Citation>Akter M, Cui H, Chen YH, Ding B, 2022. Generation of gene-corrected isogenic control cell lines from a DYT1 dystonia patient iPSC line carrying a heterozygous GAG mutation in TOR1A gene. Stem Cell Res. 62, 102807 10.1016/j.scr.2022.102807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2022.102807</ArticleId><ArticleId IdType="pmc">PMC9366766</ArticleId><ArticleId IdType="pubmed">35533513</ArticleId></ArticleIdList></Reference><Reference><Citation>Akter M, Ding B, 2022. Modeling Movement Disorders via Generation of hiPSC-Derived Motor Neurons. Cells 11 (23), 3796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9737271</ArticleId><ArticleId IdType="pubmed">36497056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepehrimanesh M, and Ding B (2020). Generation and optimization of highly pure motor neurons from human induced pluripotent stem cells via lentiviral delivery of transcription factors. American Journal of Physiology-Cell Physiology 319, C771&#x2013;C780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654652</ArticleId><ArticleId IdType="pubmed">32783653</ArticleId></ArticleIdList></Reference><Reference><Citation>Szewczyk B, G&#xfc;nther R, Japtok J, Frech MJ, Naumann M, Lee HO, Hermann A, 2023. FUS ALS neurons activate major stress pathways and reduce translation as an early protective mechanism against neurodegeneration. Cell Rep. 42 (2), 112025.</Citation><ArticleIdList><ArticleId IdType="pubmed">36696267</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>